Evidence map›Paper›PMID 36076354›Full record

ReviewVascular2024

Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies.

Mateo Porres-Aguilar, Debabrata Mukherjee, S Claudia Didia, Alejandro Lazo-Langner

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mateo Porres-AguilarDepartment of Internal Medicine, Divisions of Hospital and Adult Clinical Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.ORCID 0000-0002-2180-3000
Debabrata MukherjeeDivision of Cardiovascular Diseases, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.ORCID 0000-0002-5131-3694
S Claudia DidiaDepartment of Internal Medicine, Divisions of Hospital and Adult Clinical Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L. Foster School of Medicine, El Paso, TX, USA.
Alejandro Lazo-LangnerDivision of Hematology, Departments of Medicine and Epidemiology/Biostatistics, Western University, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel coronavirus 2019 (COVID-19) represents a significant risk factor for the development of venous thromboembolism (VTE) in hospitalized with both moderate and severe/critical COVID-19. Herein, we present a brief updated review on emerging robust data on diverse thromboprophylaxis strategies used to mitigate VTE complications, as well as a personal point of view of current controversies in regards the use of therapeutic and prophylactic anticoagulation strategies, particularly in the moderately-ill subgroup of patients with COVID-19.

Indexed as

COVID-19Venous ThromboembolismAnticoagulantsBlood CoagulationHumansSARS-CoV-2AnticoagulantsCOVID-19heparinsoutcomestherapeutic anticoagulationthromboprophylaxisvenous thromboembolism

Identifiers

PMID36076354
PMCPMC9459371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.